Yves Verboven

Yves leads the  Access & Economic Policies team we focus on European legislative and research initiatives in fields as  procurement, health technology assessment, evidence generation representing the medtech industry view and  deploying own initiatives striving to have a timely access for medical technologies and solutions and have these appropriately used and rewarded.Yves has an applied science and engineering background with further education in Business administration and health economics. Yves considers the area of medical technologies which transfers the engineering world into something as good and valuable as health, a pre-requisite  for well-being and happiness, a great motivator. Together with the team his focus is not only on the health issue challenges but also to the health system challenges, to offer best care and to do this without waste, inefficiency, complication and see this incorporated into the policies when assessing medical technology. This supports a change to a value-based model of access and awarding of new medical technology value propositions.In the  medtech industry Yves has expertise in the field of clinical engineering, first in human studies, clinical and health economic outcomes trials and analysis, reimbursement, and then, after moving to MedTech Europe,  with a focus on policies and advancing the medtech access model striving to a value-based access model, and having the appropriate instruments in place to award and reward the value of medical technology.In his free time, Yves loves to fly over the waves and lakes steering a catamaran.

Editors’ Note: This blog is part 1 of a series on the MEAT value-based procurement project, an initiative that advocates towards a shift from price-based procurement of medical technology towards value-based procurement. It does so by defining a Most Economically Advantageous Tendering (MEAT) framework that includes the value of medical technologies, services and solutions in procurement processes across Europe. Read part 2 and part 3 . If you would like to contribute please contact the MedTech Views editorial team at info@medtechviews.eu . MedTech Europe has partnered with The Boston Consulting Group to define a new framework for most economically advantageous tendering in medtech. One of the major challenges we face as a society is growth in the demand for, and cost of, health care services; growth which continues despite myriad efforts by governments, health systems, and payers to contain it. At the same time, quality of care is highly variable. For example, if you were to undergo a radical prostatectomy even in the Netherlands, you would want to choose your hospital carefully. The worst performing hospitals there have nine times higher complication rates post-surgery than the best performing hospitals. This variation in outcomes is by no means an exception, and it highlights the lack of focus and lack of data on what patients care about most – outcomes. In their book "Redefining Health Care," Michael Porter and Elizabeth Teisberg define value in health care as "the health outcomes achieved per dollar spent", a definition that lays the foundation for value-based health care. This concept is increasingly being applied as the key paradigm by which to measure health delivery. It has the potential to align all stakeholders: patients, clinicians, policymakers, payers and industry around a common viewpoint, and is an especially attractive way to shift the thinking from considering cost and...
First off, let’s start with some background. The first question that comes to mind would be: “What is the EUnetHTA Joint Action 2?” Briefly put, EUnetHTA, the European Network of Health Technology Assessment, is a joint initiative of the European Commission and the relevant agencies in the Member States, aiming to strengthen cross-border HTA collaboration.
Health technology assessment medical devices
The current voluntary cooperation of Health Technology Assessment (HTA) agencies organised within EUnetHTA indicates that HTA is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related to the use of a health technology.
Ever since the end of WWII, the reigning clinical philosophy was one whereby there was no limit on medical treatment. From the 80s onwards, this philosophy shifted towards a more balanced approach whereby the benefit of the treatment had to outweigh the potential risks associated with it, with evidence-based medicine being the concept used to assess a new treatment.